Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | FCER2 | P06734 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030629 | 1.00 | CYP2A6 (0.50) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL22255835 | 0.83 | CYP2A6 (0.46) | CYP2A6ASIC3LOXL2AGXTMMP1 | |
| SCHEMBL514507 | 0.82 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL1062090 | 0.82 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL4626056 | 0.82 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL16461209 | 0.80 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL631264 | 0.76 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL29534459 | 0.76 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| SCHEMBL7026459 | 0.75 | AGXT (0.49) | CYP2A6ASIC3LOXL2AGXTBCL2L1 | |
| Trifluoroacetic Acid SCHEMBL6161390 | 0.75 | S1PR4 (0.46) | CYP2A6ASIC3LOXL2AGXTBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | CYP2A6 4602/4885ASIC3 2241/4885LOXL2 4561/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | CYP2A6 4862/4885ASIC3 1824/4885LOXL2 4577/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | CYP2A6 1254/4885ASIC3 958/4885LOXL2 2542/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | CYP2A6 4863/4885ASIC3 2181/4885LOXL2 4530/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | CYP2A6 4278/4885ASIC3 4365/4885LOXL2 3701/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | CYP2A6 4343/4885ASIC3 3081/4885LOXL2 3892/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | CYP2A6 4602/4885ASIC3 2241/4885LOXL2 4561/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | CYP2A6 4537/4885ASIC3 2688/4885LOXL2 1624/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | CYP2A6 4800/4885ASIC3 2215/4885LOXL2 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.